Management and Treatment of Recurrent Epithelial Ovarian Cancer

被引：45

作者：

Armbruster, Shannon ^{[1
]}

Coleman, Robert L. ^{[1
]}

Rauh-Hain, Jose Alejandro ^{[1
,2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Unit 1362, 1155 Herman Pressler, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Hlth Serv Res, Unit 1444, 1515 Holcombe Blvd,POB 301402, Houston, TX 77230 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2018年 / 32卷 / 06期

关键词：

Ovarian cancer; Recurrence; PARP; Immunotherapy; Chemotherapy; Secondary cytoreduction; PLATINUM-RESISTANT OVARIAN; PEGYLATED LIPOSOMAL DOXORUBICIN; SECONDARY CYTOREDUCTIVE SURGERY; CONTROLLED PHASE-III; DOUBLE-BLIND; OPEN-LABEL; MAINTENANCE THERAPY; PRIMARY PERITONEAL; TUMOR ANGIOGENESIS; ANTITUMOR-ACTIVITY;

D O I：

10.1016/j.hoc.2018.07.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Most women with advanced epithelial ovarian cancer will experience many episodes of recurrent disease with progressively shorter disease-free intervals. For women whose disease continues to respond to platinum based drugs, the disease can often be controlled for 5 years or more. Enormous progress has been made in the management of this disease, and new targeted treatments such as antiangiogenic drugs, poly(adenosine diphosphate-ribose) polymerase inhibitors, and immune checkpoint inhibitors offer potential for improved survival. A variety of combination strategies are being evaluated to leverage these agents. The role of secondary cytoreduction remains a topic of active investigation.

引用

页码：965 / +

页数：19

共 70 条

[61] Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A gynecologic oncology group study [J].

Rose, PG ;

Blessing, JA ;

Mayer, AR ;

Homesley, HD .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :405-410

[62] Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer [J].

Safra, Tamar ;

Menczer, Joseph ;

Bernstein, Rinat ;

Shpigel, Shulem ;

Inbar, Moshe J. ;

Grisaru, Dan ;

Golan, Abraham ;

Levy, Tally .

GYNECOLOGIC ONCOLOGY, 2007, 105 (01) :205-210

[63] Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer [J].

Stockler, Martin R. ;

Hilpert, Felix ;

Friedlander, Michael ;

King, Madeleine T. ;

Wenzel, Lari ;

Lee, Chee Khoon ;

Joly, Florence ;

de Gregorio, Nikolaus ;

Angel Arranz, Jose ;

Mirza, Mansoor Raza ;

Sorio, Roberto ;

Freudensprung, Ulrich ;

Sneller, Vesna ;

Hales, Gill ;

Pujade-Lauraine, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (13) :1309-+

[64]

Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/S1470-2045(16)30559-9, 10.1016/s1470-2045(16)30559-9]

[65] A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection [J].

Tian, Wen-Juan ;

Chi, Dennis S. ;

Sehouli, Jalid ;

Trope, Claes G. ;

Jiang, Rong ;

Ayhan, Ali ;

Cormio, Gennaro ;

Xing, Yan ;

Breitbach, Georg-Peter ;

Braicu, Elena Ioana ;

Rabbitt, Catherine A. ;

Oksefjell, Halldis ;

Fotopoulou, Christina ;

Meerpohl, Hans-Gerd ;

du Bois, Andreas ;

Berek, Jonathan S. ;

Zang, Rong-Yu ;

Harter, Philipp .

ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (02) :597-604

[66] Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. [J].

Varga, Andrea ;

Piha-Paul, Sarina Anne ;

Ott, Patrick Alexander ;

Mehnert, Janice M. ;

Berton-Rigaud, Dominique ;

Johnson, Elizabeth A. ;

Cheng, Jonathan D. ;

Yuan, Sammy ;

Rubin, Eric H. ;

Matei, Daniela E. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[67] Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients [J].

Wagner, U. ;

Marth, C. ;

Largillier, R. ;

Kaern, J. ;

Brown, C. ;

Heywood, M. ;

Bonaventura, T. ;

Vergote, I. ;

Piccirillo, M. C. ;

Fossati, R. ;

Gebski, V. ;

Lauraine, E. P. .

BRITISH JOURNAL OF CANCER, 2012, 107 (04) :588-591

[68] Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice [J].

Yoneda, J ;

Kuniyasu, H ;

Crispens, MA ;

Price, JE ;

Bucana, CD ;

Fidler, IJ .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (06) :447-454

[69] Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort [J].

Zang, R. Y. ;

Harter, P. ;

Chi, D. S. ;

Sehouli, J. ;

Jiang, R. ;

Trope, C. G. ;

Ayhan, A. ;

Cormio, G. ;

Xing, Y. ;

Wollschlaeger, K. M. ;

Braicu, E. I. ;

Rabbitt, C. A. ;

Oksefjell, H. ;

Tian, W. J. ;

Fotopoulou, C. ;

Pfisterer, J. ;

du Bois, A. ;

Berek, J. S. .

BRITISH JOURNAL OF CANCER, 2011, 105 (07) :890-896

[70] Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer [J].

Zhang, L ;

Conejo-Garcia, JR ;

Katsaros, D ;

Gimotty, PA ;

Massobrio, M ;

Regnani, G ;

Makrigiannakis, A ;

Gray, H ;

Schlienger, K ;

Liebman, MN ;

Rubin, SC ;

Coukos, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (03) :203-213

← 1 2 3 4 5 6 7 →